TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PROphylactic Manual RotatIon in the Second stagE of Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant~* Age 18 years or greater~* English-speaking~* Nulliparous~* Singleton gestation~* Planning a vaginal birth~* Have neuraxial anesthesia~* Term gestation (≥37 weeks' gestation)~* Ruptured membranes~* Complete cervical dilation~* Cephalic presenting fetus~* Fetus presenting with occiput posterior or occiput transverse position confirmed by ultrasound~Exclusion Criteria:~* Pregnancies with intrauterine fetal demise~* Pregnancies affected by major fetal anomaly~* Maternal or fetal contraindication to vaginal delivery, including operative vaginal delivery~* Fetal malpresentation, including brow or face presentation~* Category III fetal heart rate tracing at time of randomization~* Duration of pushing already exceeding 15 minutes in the second stage of labor~* Lack of other inclusion criteria as described above

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prophylactic manual rotation (Type: EXPERIMENTAL): Prophylactic manual rotation involves a vaginal examination performed with an obstetric provider's hands to turn the baby from a position in which the baby's face is looking up in the direction of the ceiling (occiput posterior) or to the side (occiput transverse) to a position in which the baby's face is looking down in the direction of the mother's spine (occiput anterior). Prophylactic manual rotation will occur at the initiation of pushing once the individual achieves complete cervical dilation.
- Sham rotation (Type: SHAM_COMPARATOR): Sham rotation involves a vaginal exam that obstetric providers commonly do with their hands to assess cervical dilation and fetal position during routine labor, and will occur at the initiation of pushing once the individual achieves complete cervical dilation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of a Melatonin Supplementation on the Quality of Life in Elderly Metastatic Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> = 70 years.~* Performance status \< = 2 (WHO criteria)~* Life expectancy \> 3months~* A patient with solid tumor locally advanced or metastatic~* Indication of systemic anticancer treatment : oral or IV chemotherapy, endocrine therapy, target therapy or immunotherapy~* MMS-orientation ≥ 7 (geriatric Mini Mental State face-to-face questionnaire)~* Able to swallow and retain oral treatment~* Patient who signed the participation consent before entering the trial~* Patient able to read, write and understand French.~* Affiliation to the french social security scheme (or beneficiary of such a scheme) under the terms of the law of 9 August 2004.~Exclusion Criteria:~* Haematological cancers~* Renal failure or hepatic failure~* Auto-immune disease~* Diagnosed neurodegenerative diseases~* Unability to fill out questionnaires~* melatonin treatment ongoing or completed for less than 3 months~* Treatment with an investigational drug, participation to another therapeutic clinical trial within \<30 days~* Hypersensitivity to melatonin or any of the excipients~* Current Treatment with fluvoxamine, 5- or 8-methoxypsoralen, cimetidine, estrogen~* A history of known or suspected excessive alcohol use.~* Patient refusing to participate and / or unable to give informed consent~* Patient unable to complete the questionnaires even with the help of a relative or a nurse~* Patient does not have the capacity to comply with the study requirements~* Patient deprived of liberty by a court or administrative.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group Melatonin (Type: EXPERIMENTAL): standard anticancer treatment + 3-month of melatonin supplementation
- Group Placebo (Type: PLACEBO_COMPARATOR): standard anticancer treatment + placebo (3 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Mitral Valve Reconstruction in Chronic Heart Failure (CHF): Identification of Predictors for a Successful Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 years old~2. Dilatative Cardiomyopathy with LVEF \< 35%~3. NYHA III oder IV under maximal medical treatment~4. Angiographic and hemodynamic MI \> II° (LAP- mean pressure \> 15-20 mmHg; LA v-wave-oder PCWP v-wave \> 35 mmHg under exercise)~5. Echocardiographic MI \> II°~6. At least 1 hospitalization for heart failure before OP~Exclusion Criteria:~1. Secondary Cardiomyopathy by vitium cordis~2. Planned secondary procedure like CABG, aortic valve surgery, surgery of the tricuspid valve etc~3. Inclusion in another trial~4. Euro-Score \> 30%~5. Former valve operation or CABG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Surgical mitral valve reconstruction
- 2 (Type: NO_INTERVENTION): conservative treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Device for Monitoring Pain During Intraoperative, Pre/Post Surgical Periods: Comparison With Standard of Care Monitoring

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 or older~* post thoracotomy with a consult placed to the acute pain service on post-op day 0 for management of a PCA or epidural~* mental status permits patient to reliably press a button to record pain or administer medications~* must be hemodynamically stable~* must be able to physically use the MyHealth trends diary (press a button)~* supplies written informed consent.~Exclusion Criteria:~* less than 18 years of age~* has any underlying or current medical condition, which, in the opinion of the Investigator, would interfere with the use of the MyHealth trends device (e.g. severe psychosis, quadrapalegic, etc.)~* Subject necessitates ICU care

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Baeta (Type: EXPERIMENTAL): These patients receive the Baeta device and take it home.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Expression of Endometrium During Window of Implantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age: 30-44 years~* BMI: 18\~30 kg/m2~* Implantation failure at least two times~Exclusion Criteria:~* Primary ovarian insufficiency~* Congenital uterine anomaly~* Severe intrauterine adhesion~* Malignancy~* Donor cycle

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 44 Years
- Healthy Volunteers: f

Study Arms:
- Natural cycles (Type: None): Endometrium will be sampled at the day of LH surge + 7 days.
- Artificial cycles (Type: None): Endometrium will be sampled at the day of P4 + 5 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy of Octenisept® in Patients With Chronic Wounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients of at least 18 years at the time of consent~* Patients with a venous leg ulcer (Ulcus cruris)~* Patients with a chronic leg ulcer~* Females of childbearing potential who are willing to comply with any applicable contraceptive requirements of the protocol~* Negative pregnancy test~* Satisfactory medical assessment~* Ability to provide written informed consent~* Signed declaration of consent~* Willingness to co-operate~Exclusion Criteria:~* Pregnant or lactating women and women not using contraception~* Known history of alcohol or drug abuse~* Use of any antibiotic medication within the last 7 days prior to the first dose~* Patients with serious concomitant disease~* Patients with a coagulation disorder~* Known history of allergic reactions attributed to octenisept® or one of its compounds~* Participation in another clinical trial within the last 30 days before randomization~* Concomitant treatment with other preparations that interfere with the trial preparation or the disease~* Absence of declaration of consent~* Doubt about willingness to co-operate~* Non-fulfilment of the inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- verum (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Low-Intensity Physical Therapy for Prevention of Pre and Postpartum Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Nulliparous, pregnant women, 18 years or older~* Less than 20 weeks gestation~* Able to give consent and who are willing to participate~Exclusion Criteria:~* Multiparous women~* Women presenting after 20 weeks gestation~* History of urinary incontinence~* Mentally impaired women and women who have neurological impairment affecting ability to perform pelvic floor muscle training

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Neuromuscular Changes In Small For Gestational Age Children During Somatropin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-pubertal boys between 6 and 10 years of age or girls between 6 and 9 years of age.~* Birth length- and/or birth weight-SDS adjusted to gestational age \< -2.0 (Voigt et al. 2002, Voigt et al. 2006 or Lawrence et al. 1989).~* Current height-SDS \< -2.5 (Brandt/Reinken 1992) and parental adjusted height-SDS below -1 (Hermanussen and Cole 2003).~* Growth velocity SDS \< 0 during the last year before inclusion (Brandt/Reinken 1988).~Exclusion Criteria:~* Severe SGA (birth weight or length \< -4 SD) and clinically relevant dysmorphic features.~* Severe pre-maturity (GA \< 32 weeks of gestation).~* Severe perinatal complications like asphyxia, sepsis, necrotizing enterocolitis (NEC), respiratory distress syndrome, if associated with long-term sequelae (like short bowel syndrome, bronchopulmonary dysplasia (BPD), cerebral palsy etc).~* Inability to perform one- or two leg jumps from a standing position.~* Prior GH treatment.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: ACTIVE_COMPARATOR): Somatropin for 12 months
- Control Group (Type: OTHER): In the first 6 months no intervention, afterwards Somatropin for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Dopaminergic Denervation by DaTSCAN Brain Scintigraphy Using a New Multipurpose CZT System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients referred to our Nuclear Medicine department for DaTSCAN scintigraphy.~Exclusion Criteria:~* Under 18 years-old patients.~* Pregnant women or at risk of pregnancy.~* Breast feeding.~* Painful patients.~* Patients under guardianship.~* Patients in whom a standard examination is not feasible (agitation).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DaTSCAN brain scan images from the new CZT SPECT system (Type: EXPERIMENTAL): All patients will undergo additional SPECT acquisition (30min added time approximately), with no added radiation, with both new multipurpose CZT camera (StarGuide system, GE Healthcare, Haïfa, Israel) and conventional SPECT camera (Discovery 670, GE Healthcare, Haïfa, Israel)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ODEN Trial: Option vs. Denali IVC Filters

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients scheduled for IVC filter placement at UCSF Moffitt, Mission Bay and Mount Zion hospitals Interventional Radiology~2. 18+~Exclusion Criteria:~1. Necessity of permanent IVC filter.~2. Genetic or physical abnormalities of the inferior vena cava~3. Circumstances that in the opinion of the primary investigator, patient would be a poor candidate either due to complications in medical condition or lack of ability for follow up.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Denali (Type: EXPERIMENTAL): Denali IVC Filter
- Option (Type: EXPERIMENTAL): Option Elite IVC Filter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Oxygen Interventions and Defibrillator Efficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Atrial fibrillation or -flutter~Exclusion Criteria:~* Patients \<18 years of age~* Pregnancy~* Haemodynamically unstable patients~* Other arrhythmias~* Untreated hyperthyroidism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Standard: Oxygen / LIFEPAK 20) (Type: EXPERIMENTAL): 1. Intervention: Cardioversion with a biphasic truncated exponential waveform~2. Intervention: Hyperoxia during cardioversion
- 2 (room air / LIFEPAK 20) (Type: ACTIVE_COMPARATOR): 1. Intervention: Cardioversion with a biphasic truncated exponential waveform~2. Intervention: Normoxia during cardioversion
- 3 (Oxygen / Schiller Defigard 5000) (Type: ACTIVE_COMPARATOR): 1. Intervention: Cardioversion with a pulsed biphasic waveform~2. Intervention: Hyperoxia during cardioversion
- 4 (Room air / Schiller Defigard 5000) (Type: ACTIVE_COMPARATOR): 1. Intervention: Cardioversion with a pulsed biphasic waveform~2. Intervention: Normoxia during cardioversion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of G-CSF in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria: Patients with~* Clinical significant alcohol intake history (men over 50g within 3 months, women over 40g within 3 months)~* modified DF score greater than or equal to 32~* Transjugular liver biopsy shows typical feature of alcoholic hepatitis or meet the clinical diagnosis (total serum bilirubin level over 5 mg/dL, aspartate aminotransferase/alanine aminotransferase ratio \>2, aspartate aminotransferase \< 300 IU/L)~* Included patients should meet the all above criteria and Lille score \> 0.16 at the day 7 of prednisolone 40mg (or 32 mg of methylprednisolone) daily treatment.~Exclusion Criteria: Patients with~* hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti-HCV), or anti-human immunodeficiency virus (HIV) (+)~* Malignancy including hepatocellular carcinoma~* Portal vein thrombosis, hemochromatosis, autoimmune hepatitis, Wilson's disease, alpha-1-antitrypsin deficiency~* Pregnancy, breast feeding, or who refuses contraception, or who cannot do contraception~* History of adverse event including allergic response, hypersensitivity to G-CSF~* Hypovolemic shock due to gastrointestinal hemorrhage or who need packed red blood cell (RBC) transfusion more than 3 units or increased modified discriminant factor (DF) score greater or equal to 32 from below 32 due to gastrointestinal hemorrhage~* Sepsis or uncontrolled acute infection~* Hepatic encephalopathy grade 3-4~* History of steroid or pentoxifylline treatment within 3 months~* Myeloblast on peripheral blood smear test~* Critical comorbidities (type I hepatorenal syndrome, serum creatinine \>2.5mg/dL, heart failure, pulmonary disease, psychiatric disease, acute pancreatitis etc.)~* Who refuses to participate in clinical trial

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- G-CSF + steroid in partial responder (Type: EXPERIMENTAL): Patients who are randomized to prednisolone plus G-CSF treatment group in patients with partial responder to prednisolone therapy.
- Placebo + steroid in partial responder (Type: PLACEBO_COMPARATOR): Patients who are randomized to prednisolone plus placebo treatment group in patients with partial responder to prednisolone therapy.
- G-CSF in null responder to steroid (Type: EXPERIMENTAL): Patients who are randomized to G-CSF treatment group in patients with null responder to prednisolone therapy.
- Placebo in null responder to steroid (Type: PLACEBO_COMPARATOR): Patients who are randomized to placebo treatment group in patients with null responder to prednisolone therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Age \> 18 years~* Hemoglobin levels between \[ \> 9g/dl - \< 11 g/dl \] .~* Patient requiring erythropoietine beta treatment for a foreseeable duration of at least 8 weeks under the same chemotherapy protocol.~* Patient with cancer undergoing chemotherapy~* Patient without EPO within 6 months prior to current chemotherapy.~* WHO 2 performance status (Appendix 1).~* Patient information and signature of informed consent or legal representative~Exclusion criteria :~* Hemoglobin \< 9 g/dl or \> 11 g/dl~* Patient with cancer not treated with chemotherapy (targeted therapy, hormone therapy, etc...)~* Patient with cancer treated with concomitant radiation chemotherapy.~* Co-treated with Epo beta and scheduled transfusion prior to inclusion.~* Hypersensitivity to the active substance or one of the NeoRecormon excipients®~* Poorly controlled high blood pressure~* Pregnant woman, likely to be pregnant or breastfeeding,~* Persons deprived of liberty or under guardianship,~* Unable to undergo medical follow-up for geographic, social or psychological reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Erythropoietin beta (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Movement and Sensation for Advanced Prosthetic Hands

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patient has previously undergone a transradial (below elbow) or transhumeral (above elbow) amputation.~Exclusion Criteria:~1. Pregnancy~2. Incarceration~3. Inability to consent~4. Serious, untreated comorbidity~5. Patient is diagnosed with a medical condition(s) that seriously increase the risk of electrode implantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Transradial or Transhumeral amputees (Type: None): High-count microelectrode arrays are implanted into the upper limb peripheral nerves of transradial or transhumeral amputees.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility